Nuvalent Begins Phase 1 Trial for New HER2-Selective Lung Cancer Treatment
Author: Benzinga Newsdesk | July 22, 2024 06:31am
Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the initiation of HEROEX-1, its Phase 1a/1b clinical trial evaluating its novel HER2-selective inhibitor, NVL-330, for pre-treated patients with HER2-altered non-small cell lung cancer (NSCLC).
Posted In: NUVL